DEERFIELD BEACH, Fla. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Regulatory Information:
Voluntis (Paris:ALVTX) (Euronext Progress Paris, Ticker: ALVTX – ISIN: FR0004183960) a pacesetter in digital therapeutics, introduced in the present day a collaboration with Broward Well being, a public well being system within the U.S. The partnership will give attention to conducting a real-world analysis of Oleena®, a digital utility that assists sufferers in managing their signs.
As a part of the collaboration, Oleena®, a FDA-authorized digital therapeutic utility developed by Voluntis for sufferers with most cancers, can be offered to sufferers with HR+/HER2- metastatic breast most cancers to assist them in self-managing signs and negative effects of their situations and coverings. The scientific analysis will begin enrolling sufferers in 2021, following an preliminary deployment of Oleena at Broward Well being North.
The companions will conduct an evaluation of the real-world impression of the answer as a part of the Expertise-Enabled Metastatic Breast Most cancers Affected person Training Program which focuses on educating sufferers with HR+/HER2- metastatic breast most cancers and their caregivers. Oleena® can be included in this system to assist sufferers enhance their understanding of and participation of their care plan.
As one of many nation’s largest public well being techniques, Broward Well being is dedicated to offering high quality care to Broward County residents whereas rising entry to healthcare providers. By means of this partnership, the 2 organizations will consider how a prescribed digital therapeutic utility can assist distant symptom administration for sufferers with most cancers.
Oleena® embeds scientific algorithms right into a user-friendly utility that gives real-time, personalised suggestions for the administration of signs at residence. Moreover, care groups entry the automated triage features that assist monitor sufferers and prioritize focused intervention. With this joint initiative, the companions goal to boost the standard of care and outcomes whereas decreasing pointless ER visits and hospitalizations that consequence from untreated signs.
In preparation for the scientific analysis, through the design section, particular consideration was paid to optimizing the consumer expertise, answering well being literacy challenges and supporting a number of languages. This collaboration demonstrates Broward Well being and Voluntis’ willingness and dedication to boost healthcare supply and assist cut back disparities amongst sufferers.
“With Oleena®, Broward Well being North is the primary public hospital in South Florida to guage a digital therapeutic to assist most cancers symptom administration and distant affected person monitoring,” stated Mehmet Hepgur, M.D., an oncologist with the Broward Well being Doctor Group. “We’re delighted to work with Voluntis to boost scientific follow-up and streamline the connection between sufferers and their care workforce.”
Dr. Geneviève d’Orsay, Chief Medical Officer at Voluntis, stated: “We’re excited to allow Broward Well being sufferers’ to learn from Oleena® and get each day assist on their most cancers journey. We stay up for our steady collaboration with the Broward Well being workforce so as to advance the real-world proof round digital therapeutics in oncology.”
About Broward Well being
Broward Well being, offering service for greater than 80 years, is a nationally acknowledged system in South Florida that provides world-class healthcare to all. The Broward Well being system contains the statutory educating hospital Broward Well being Medical Middle, Broward Well being North, Broward Well being Imperial Level, Broward Well being Coral Springs, Salah Basis Youngsters’s Hospital, Broward Well being Weston, Broward Well being Neighborhood Well being Companies, Broward Well being Doctor Group, Broward Well being Pressing Care, Broward Well being Worldwide, and Broward Well being Basis. For extra data, go to BrowardHealth.org.
Voluntis creates digital therapeutics that empower individuals with continual situations to self-manage their remedy each day, thus enhancing real-world outcomes. Voluntis’ options, combining cellular and net apps, use scientific algorithms to ship personalised suggestions to sufferers and their care groups. For instance, these suggestions are used to regulate remedy dosage, handle negative effects or monitor signs. Leveraging its Theraxium know-how platform, Voluntis has designed and operates a number of digital therapeutics, particularly in oncology and diabetes. Voluntis has long-standing partnerships with main life science corporations. Based mostly in Cambridge, MA, and Paris, France, Voluntis is a founding member of the Digital Therapeutics Alliance. For extra data, please go to: www.voluntis.com
Mnemo: ALVTX – ISIN: FR0004183960
This press launch incorporates sure forward-looking statements regarding Voluntis group and its enterprise, together with its prospects and product candidate growth. Such forward-looking statements are based mostly on assumptions that Voluntis considers to be cheap. Nevertheless, there may be no assurance that the estimates contained in such forward-looking statements can be verified, which estimates are topic to quite a few dangers together with the dangers set forth within the 2019 annual monetary report and the 2020 half-year monetary report revealed by Voluntis respectively on April 30, 2020 and September 29, 2020 (a duplicate of which is offered on www.voluntis.com) and to the event of financial situations, monetary markets and the markets by which Voluntis operates. The forward-looking statements contained on this press launch are additionally topic to dangers not but recognized to Voluntis or not at the moment thought-about materials by Voluntis. The incidence of all or a part of such dangers may trigger precise outcomes, monetary situations, efficiency or achievements of Voluntis to be materially completely different from such forward-looking statements. Voluntis expressly declines any obligation to replace such forward-looking statements.